Corbus Pharmaceuticals Holdings Inc

NASDAQ: CRBP
$35.54
-$2.20 (-5.8%)
Closing price April 24, 2024
Corbus Pharmaceuticals Holdings Inc is a pioneering biopharmaceutical company focused on creating innovative treatments for serious illnesses. With a robust pipeline that includes CRB-701, a targeted therapy for cancer, and lenabasum, a novel treatment for inflammation and fibrosis, Corbus is at the forefront of medical research. The company also explores treatments for obesity and related metabolic diseases with CRB-913. Based in Norwood, Massachusetts, and founded in 2009, Corbus is committed to advancing healthcare through groundbreaking research and partnerships, such as its collaboration with Jenrin Discovery, LLC.

Buffett Can't Get Enough of This Stock, Plus Other Insider Buying
Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying of communication and aviation stocks in the past week.
Trey Thoelcke
Published:

Another Huge Buffett Purchase Highlights Recent Insider Buying
Another huge Warren Buffett purchase highlighted the past week's insider buying, and a couple of IPOs also prompted insiders to action.
Trey Thoelcke
Published:

Insider Buying at These Biotechs Is Huge
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Trey Thoelcke
Published:

These Are The Robinhood Stocks With The Highest Analyst Rating
Robinhood has become the dominant discount brokerage platform over the last year. It had 4.3 million average revenue trades in June, which is a critical metric in the industry. This is higher than...
Douglas A. McIntyre
Published: